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STIMULATED by the encouraging report by Watson and Turner (1959) ofthe use
of a combined regimen of Thiotepa and testosterone in the treatment of breast
cancer, it was considered desirable to attempt to confirm the findings of the above
report and to compare the efficacy ofthis form oftreatment with that ofthe ortho-
dox forms of treatment in disseminated breast cancer, with a view to its possible
use at a later time in less advanced cases.
The patients were drawn from those attending a combined Surgical/Radio-
therapy Clinic. Only cases ofbreast cancer that had progressed without, or in spite
of previous treatment to the stage where systemic rather than purely local treat-
ment was indicated were included in this series. Provided that the patient appeared
to be equally suitable either for some form oforthodox treatment or for treatment
by testosterone and Thiotepa, the decision whether a particular patient should be
treated by orthodox methods or Thiotepa and testosterone was made by reference
to a random selection table compiled by a statistician.
Once patients had been accepted into this series, their subsequent progress was
carefully followed, and those who have survived still remain under our care.
Orthodox treatment
As can be seen from Table I, the majority of the patients in this group were
treated by a combination ofoophorectomy and adrenalectomy. The treatment was
said to have failed ifthe patient died following the selected treatment, ifthere was
no response, if any palliation achieved ceased, or if although a favourable tumour
TABLE I.-Treatment Given
Method of treatment . Number of patients
Orthodox
Oophorectomy 1
Oophorectomy + adrenalectomy 13
Deep X-ray therapy + testosterone 1
Pituitary implant 1
Nil 1
Deep X-ray therapy 2
Stilboestrol 1
20
Thiotepa + testosterone
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response resultedit was difficult to controlthe patient satisfactorily onreplacement
therapy.
Thiotepa and testosterone treatment
Dose regimen.-Both drugs were given by intramuscular injection.
It was decided to aim at giving an initial series ofthree courses ofThiotepa and
testosterone. Each course was of six weeks' duration. Intervals oftwo weeks and
four weeks separated the first and second, and the second and third courses respec-
tively.
During the first week of each course, 200 mg. of testosterone only was given
daily. Inthe second, third andfourth weeks Thiotepa was added in doses of30 mg.
on Mondays, Wednesdays and Fridays, except for the first Monday of treatment
when a dose of 15 mg. was given. In the fifth and sixth weeks testosterone was
given. The full course consisted of 285 mg. of Thiotepa and 6 g. of testosterone.
Haematological examinations were made every other day during treatment and
continued if there had been any depression of blood forming elements until the
blood picture returned to normal. The dose regimen is shown in Fig. 1.
It was our practice to stop the Thiotepa and testosterone regimen oftreatment
if haematological changes were so severe as to be a cause of concern, and to give
subsequently some other form of treatment. On the other hand, patients who
showedimprovementfollowingtheinitialthreecoursesofThiotepaandtestosterone,
and whose haemopoietic system was not seriously adversely affected were given
further courses ofThiotepa and testosterone-one patient having as many as seven
courses in all over a period of 21 years.
The treatmentwas saidto have failedwhen anypalliation achieved ceased, and,
in addition, if the treatment had to be discontinued because of adverse haemato-
logical changes, before symptomatic palliation was achieved.
Failure ofselected treatment
If there was no obvious beneficial response to the initial form of treatment
selected for any given patient, then the treatment was considered to have failed as
far as this series was concerned, and some other form oftreatment was instituted.
The ultimate outcome of all the patients treated is described later in order to
compare the morbidity and mortality of treatment in the two groups.
Comparison ofthe two groups ofpatients shows that thereis no major difference
between them which is likely to have led to a bias in the results oftreatment.
Frequency and nature of recurrence or dissemination which led to patient's inclusion
in this series
Table II shows the localization ofthe active tumour which led to the inclusion
of the patients in this series.
In both groups, just over 50 per cent had one category of metastases only.
There was no preponderance of any particular combination of metastatic deposit
in the others.
In general, it is recognised that bone deposits respond well to hormone surgery
and visceral metastases respond badly. Ofthe two groups, those treated by ortho-
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dox methods included 7 patients with bone deposits and 8 with visceral deposits,
and those treated by Thiotepa and testosterone included 6 patients with bone
deposits and 7 with visceral deposits.
Pathology
In each group, the majority of patients had been proved to have a carcinoma
of the breast by histological examination of the primary tumour. The types of
tumour concerned are shown in Table III and appear to be comparable in the two
groups.
THIOTEPA TREATMENT.SCHEME 2w mg.
-K WEEKt WIEK WEE WEEK
1 2 3 .4 5
s L *.vTtT. *vT |*E 1 TtETvvT1
FIRST
COURSE
WEEK
lIiiIII illGll:-- Jo o11111 l
In.IORA 1
Jm.g
SECOND
COURSE
I I I]II I I I I 1-[ 1JJ
(two weksrat)
TLS1W EON WEEK WEEK WEEK
9 10 11I1
T-v v I -T YTTTT -T i ITI
ESTIMATE: Hb.
AL&.CS.. every
*W.a. other
PLATELETS day
12,
12
I
FK WEEK
13
vwuw. I wwvww I , VYV I , v v v .I
HJLU$1il !IL!--1h111.11111411111.14.
~~~- r':
I rTH orTEPA I
WEEK
15
I
.1 1 11.
WEEK
16
1.
w-Br
17
11 11 1.1
WEE WEE
WEE R_
TESTSWERONE 19 20 21
;'v ,v Iv vvuvvI
18 1
(fourweks rest)
EEK waK WEEK
22 23 24
I .,y ,v yv I
FIG. 1.-Thiotepa and testosterone treatment regimen.
WEEK
14
1
THtRD:
COURSE 11IIILW IU'2I.III'l t}I["X'l|:'1-11tlI~f1'1'1'1-1-11n
.. . . . i
. . . . i -r-7-4
240
-
I I I
I
T T
I 'I'r-,Niorr.PA I I' ITHIOTEPA AND TESTOSTERONE FOR BREAST CANCER 241
TABLE II.-Localization of Active Tumour in Patients Admitted to this Series
Number of patients treated
Orthodox Testosterone
Site of tumour methods and Thiotepa
Single
Local . . . . . 4 6
Bones . 4 5
Visceral . 4 3
Total . . . . . . 12 14
Multiple
Local and visceral . . . 1 2
Local and nodes . . . 2 2
Local and bones . . 1 0
Bones and nodes . . 1 0
Visceral and nodes . . . . 2 0
Local, bones and visceral . . 1 0
Local, bones, visceral and nodes 0 1
Local, visceral and nodes . . 0 1
Total . . . . . 8 6
TABLE III.-Pathology of Primary Carcinoma of Patients Admitted to this Series
Number of patients
Orthodox Testosterone
Pathology methods and Thiotepa
Adeno carcinoma . . 6 7
Intraduct carcinoma . . 2 3
Scirrhous carcinoma . . 4 4
Anaplastic carcinoma . 4 3
No histology available . . 4 3
Age ofpatients
The age distribution ofthe two groups is not significantly different (t = 0874.
P > 0.4), the ranges being from 32 to 65 years in the Thiotepa and testosterone
group, and from 34 to 68 years in the orthodox group.
Type ofprevious treatment
Ofthe 40 patients in this series, 7 had not had any previous treatment for their
carcinoma of breast, 18 had undergone planned primary treatment by surgery
and/or radiotherapy, and 15 had also had treatment to secondary deposits subse-
quent to their primary treatment but before inclusion in this series. An analysis of
the previous treatment given to the members ofthe two treatment groups is shown
in Table IV.
Length ofprevious history
Fig. 2 and 3 and Tables V and VI include the treatment history ofeach patient
in the two groups. They showthe duration ofsymptoms beforethe first treatment,
the interval that elapsed before the first recurrence, and the point ofentry into the
series. It can be seen that:
(1) The length ofhistory before the patient first attended hospital for treatment
for carcinoma of the breast varied from 1 week to 7 years in the orthodox groupI. SCOTT BROWN, W. M. ROSS AND D. N. WALDER
TABLE IV.-Type of Treatment Given Preceding Entry into Series
Distribution in the two
treatment groups
Testosterone
Type of prior treatment Orthodox and Thiotepa Total
None . . . . 5 2 . 7
Initial
Surgery . . . . 1 1
Radiotherapy . . . 0 1 - . 18
Surgery + radiotherapy 5 10J
Initial + 8ub8equent
Surgery + radiotherapy 6 4)
Surgery + radiotherapy + 15
hormones . . . 1 2
Radiotherapy + hormones. 2 0J
and up to 2 years in the Thiotepa and testosterone group; the average was 14
months in the group treated by orthodox methods and 8- months in the group
treated by Thiotepa and testosterone. It is thus apparent that there were fewer
patients with slowly-growing tumours in the Thiotepa and testosterone group
and therefore this group was not loaded by slowly-growing tumours.
(2) The average interval from the first form oftreatment to entering the series
was 46 months in the orthodox group and 21 months in the Thiotepa and testo-
sterone group.
(3) The total length of history preceding the entry of the patient to the series
varied from 2 weeks to 10- years, the average being 60 months in the orthodox
group and 29 months in the Thiotepa and testosterone group.
The above comparisons suggest that the patients in the Thiotepa and testo-
sterone group suffered from cancers which on average were rather more rapidly
growingthan those ofpatients treatedbyorthodox methods. Ashasbeenexplained
the patients were allocated by a random method to the two groups, and analysis
ofthe two groups confirms that, in other respects, the groups were similar (Tables
II, III and IV).
RESULTS
Fig. 2 and 3 and Tables V and VI also show the length of palliation achieved
and the survival time after this palliation ceased. It can be seen that
EXPLANATION OF PLATES
FiG. 2.-Treatment history (Orthodox Group).
(a) Length of history before first attendance at hospital for treatment.
(b) Interval between first treatment and first recurrence.
(c) Interval between first recurrence and entry into series.
(d) Length of palliation by treatment in series.
(e) Length of survival without palliation.
(f) Patient still alive.
FIG. 3.-Treatment history (Thiotepa and testosterone group).
(a) Length of history before first attendance at hospital for treatment.
(b) Interval between first treatment and first recurrence.
(c) Interval between first recurrence and entry into series.
(d) Length of palliation by treatment in series.
(e) Length of survival without palliation.
(f) Patient still alive.
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TABLE V.-Treatment History (Orthodox Group)
Length of
history Interval Total
before 1st Interval Interval between 1st length of Length of
attendance between lst between 1st form of history palliation Length of
at hospital treatment recurrence treatment preceding by treat- survival
for and 1st and entry and entry entry into ment in without
treatment recurrence into series into series series series palliation
(months) (months) (months) (months) (months) (months) (months) Results
(a) (b) (c) (b + c) (a + b + c) (d) (e) (f)
Orthodox
Case No. , - _ _ .,
1 56 24 0 24 80 42 Alive
3 12 18 36 54 66 0 4 Dead
5 < 1 12 2 14 15 10 1 Dead
6 3 11 9 20 23 0 1 Dead
10 1 13 112 125 126 0 4 Dead
12 5 70 23 93 98 9 8 Dead
13 6 13 0 13 19 0 0 Dead
14 6 69 0 69 75 8 0 Dead
18 48* 0 0 0 48 6 6 Dead
20 4 8 13 21 25 6 21 Dead
22 24 48 48 96 120 0 0 Dead
23 6 0 0 0 6 18 6 Dead
25 12 54 13 67 79 30 Alive
26 <1* 0 0 0 1 0 1 Dead
31 1 39 4 43 44 12 2 Dead
32 3 95 24 119 122 0 4 Dead
34 2 106 2 108 110 0 0 Dead
35 84* 0 0 0 84 0 1 Dead
37 4 49 1 50 54 0 11 Dead
39 <1* 0 0 0 < 1 14 Alive
Average 14 46 60
* Patient's first form of treatment on entering series.
(1) At the present time, 3- years after the series was started, and 14 months
after the last patient was admitted, 3 patients in the orthodox group and 6 in the
Thiotepa and testosterone group are still alive. All of the latter 6 patients have
been given further treatment (by deep X-ray therapy or hormone treatment with
androgens and/or prednisone) since the period of control by Thiotepa and testo-
sterone ceased, with further palliation in 5.
(2) In each group, 12 patients derived some palliation from the treatment pre-
scribed initially on admission to the series, while 8 did not. Ofthose 8 showing no
apparent response, in the orthodox group no palliation was subsequently achieved
when alternative treatment was given, such as pituitary ablation, the administra-
tion of androgen after the failure of bilateral adrenalectomy, or adrenalectomy
after the failure of oophorectomy. Similarly, in the 8 showing no response in the
group treated by Thiotepa and testosterone, the employment oforthodox methods
in patients after the failure of Thiotepa and testosterone produced no response
except in one patient, whose tumour became smaller and more mobile following
high dose X-ray treatment.
(3) Ofthe 12 patients showing some response initially to treatment by orthodox
methods, 2 subsequently showed further temporary improvement when the treat-
ment was altered, for example deep X-ray therapy relieved the pain ofmetastases,
and the administration ofandrogens brought about some remission after a relapse
following an effective adrenalectomy. Similarly, 2 patients in the group treated by
Thiotepa and testosterone were improved by other treatment, namely local deep
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TABLE VI.-Treatment History (Thiotepa and Testosterone Group)
Length of
history Interval Total
before 1st Interval Interval between 1st length of Length of
attendance between 1st between 1st form of history palliation
at hospital treatment recurrence treatment preceding by treat-
for and lst and entry and entry entry into ment in
treatment recurrence into series into series series series
(months) (months) (months) (months) (months) (months)
(a) (b) (c) (b + c) (a + b + c) (d)
Thiotepa + Testosterone
Case No. -
2 4 9 1 10 14 0
4 5 8 1 9 14 11
7 12 13 0 13 25 28
8 5 6 8 14 19 8
9 8 4 22 26 34 32
11 11 38 1 39 50 26
15 4 5 6 11 15 5
16 7 9 17 26 33 4
17 4 41 7 48 52 9
19 12 15 2 17 29 0
21 6* 0 0 0 6 5
24 13 46 3 49 62 20
27 14 69 1 70 84 26
28 10 7 0 7 17 14
29 7 16 1 17 24 0
30 <-1 7 3 10 11 0
33 24 14 2 16 40 0
36 11 8 2 10 21 3
38 2 24 1 25 27 0
40 12* 0 0 0 12 0
Average 8- 21 29
* Patient's first form of treatment on entering series.
Length of
survival
without
palliation
(months) Results
(e) (f)
0
6
12
4
6
11
3
1
13
5
0
13
2
12
5
2
4
3
5
14
Dead
Dead
Alive
Dead
Alive
Alive
Dead
Dead
Dead
Dead
Dead
Alive
Alive
Dead
Dead
Dead
Dead
Dead
Dead
Alive
X-ray therapy. In one case this was necessary because it became apparent that the
Thiotepa and testosterone treatment was ineffective, and in the other case because
Thiotepa and testosterone resulted in marked blood depression and it seemed
inadvisable to continue with this form oftreatment.
(4) Ofthepatients already dead (17 inthe orthodox group and 14intheThiotepa
and testosterone group), the longest survival was 2 years, and the average in each
group 9 months.
(5) Twopatients, one ineachgroup, diedwithin a fewdaysofentering the series.
One patient died after the first injection of Thiotepa, although it seems unlikely
that this was attributable to the drug, and the other patient died of her cancer
whilst awaiting operation.
Complications
Orthodox group.-Two patients required re-admission to hospital after adrenal-
ectomy for management of electrolyte imbalance due to steroid insufficiency. Of
these, one has had one episode of electrolyte inbalance and is now very well 31
years after adrenalectomy, while the other died 11 months after bilateral adrenal-
ectomy, having had four episodes of electrolyte imbalance.
Thiotepa and testosterone group.-One patient died shortly after her first injec-
tion ofThiotepa but it was not thought that this was attributable to the drug. One
patient died of coronary thrombosis during her third course at a time when her
blood count was within normal limits.
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All patients showed a depression ofthe total white cell count below 4,000 cells
per c.mm. at some time during their treatment.
(a) Three or more complete courses ofThiotepa and testosterone were given to
6 patients, 2 ofwhomrequiredout-patient treatment withpenicillin andprednisone
for leucopenia with white cell counts of 1,400 and 900 per c. mm. respectively, and
platelet counts of 40,000 per c. mm. One of these patients eventually required
blood transfusion but both made a full haematological recovery. A third patient
required out-patient treatment for leucopenia in the fourth course and transfusion
as an in-patient in the fifth, neither ofthese courses being completed.
(b) Three or more incomplete courses were given to 4 patients. In all of these
the blood changes were severe, two having white cell counts below 800 cells per
c. mm. Two patients had to be admitted to hospital and one of these required
blood transfusion.
(c) Two courses only of Thiotepa and testosterone were given to one patient,
after which this form of treatment was abandoned not because of blood changes
but because ofthe continued advance ofthe malignant condition.
(d) One full course or less ofThiotepa and testosterone was given to 7 patients.
One of these died with melaena and petechiae, the last recorded white cell count
being 150 cells per c. mm. and the platelet count 32,000 per c. mm. The other 6 all
developed extremely low white cell and platelet counts, and required in-patient
treatment to tide them over a period of severe leucopenia. It was not considered
safe to give these patients any further treatment with Thiotepa and testosterone.
Hirsutes was a complication in about half the patients in the Thiotepa and
testosterone group. This was usually managed by the patients themselves, who at
their own expense bought depilatory cosmetic preparations which although very
satisfactory were extremely expensive.
DISCUSSION
Although it was intended to manage those patients in the Thiotepa and testo-
sterone series as out-patients, 12 of them had to be admitted to the ward during
treatment, 2 because of poor general condition and 10 because of haematological
complications.
Assessing the results obtained in these two groups, Thiotepa and testosterone
may be considered as a reasonable alternative, equally effective form oftreatment
to more orthodox methods. It is necessary, however, to recognise that there are
certain disadvantages in its use.
To the patient, a course ofThiotepa and testosterone meant frequent journeys
to hospital for injections and blood counts. As much as five half days per week
were lost in this way during each course ofThiotepa and testosterone. In addition,
many patients required admission to hospital either for closer observation, or for
further supportive treatment.
This form of treatment carried a considerable morbidity as shown by haemor-
rhagic episodes, liability to infections and agranulocytosis.
Thiotepa is a drug ofhigh toxicity for the haemopoietic system and it is clear
that it would be unwise to exceed the dosage employed in this series. In spite of
using testosterone in association with Thiotepa, depression of the haemopoietic
tissue still occurred.
It must be admitted, however, that the overall results compared favourably
with those oforthodox forms oftreatment as regards palliation.
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It is doubtful whether there is ever an occasion when Thiotepa and testosterone
would be the treatment of choice but the following conditions, or combination of
conditions, might lead to its consideration as a reasonable alternative:
(a) A lack of facilities for radiotherapy and surgery, such as might be encoun-
tered in some of the under-developed countries.
lb) A desire to avoid operation because of the temperament of the patient.
(c) Some specific contra-indication to surgery (with present day anaesthetics
and pre- and post-operative care, absolute contra-indications are rarely encoun-
tered).
(d) Technical difficulty in giving further radiotherapy because of previous
irradiation.
(e) Inability to tolerate hormone therapy because of side effects such as vomit-
ing, vaginal haemorrhage, or water and electrolyte disturbance.
It has been suggested that the beneficial effects ofthe testosterone and Thiotepa
regimen used are entirely attributable to the testosterone. Although it is not
possible to draw any conclusion about this point from the present series, we do not
subscribe to this view because we know of three patients in whom testosterone
alone was ineffective whereas testosterone and Thiotepa resulted in a period of
palliation.
CONCLUSIONS
(1) Treatment with Thiotepa and testosterone has as much value as orthodox
treatment in relieving the symptoms of and controlling disseminated carcinoma of
the breast.
(2) The patient who does not respond to Thiotepa and testosterone is unlikely
to respond more satisfactorily to orthodox treatment.
(3) When the palliation resulting from Thiotepa and testosterone ceases,
further palliation can be expected from the use of orthodox treatment.
(4) Thiotepa and testosterone treatment is prolonged and arduous. It is often
associated with considerable morbidity. Its use is not advocated in less advanced
cases, if other methods oftreatment are available.
(5) This study has confirmed the statement made by Watson and Turner (1]959)
that a regimen oftestosterone and Thiotepa can result in marked tumour inhibitory
effects in carcinoma of the breast in a proportion of cases.
Supplies of Thiotepa were kindly made available by Lederle Laboratories
Division, Cyanamid of Great Britain Limited.
We wish to thank Dr. Marchant Tulloh for help in the early stages of this
investigation, and Professor A. G. R. Lowdon and Mr. C. J. L. Thurgar for their
advice.
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